• Risen (Suzhou) Pharma Tech. Co. Ltd. v. Alzheon, Inc.Institution denied
  PTAB · Jan 13, 2023 · PGR2022-00051 · APJ Jamie T Wisz · PGR · Institution

  The Board denied institution on all challenged claims, finding no reasonable likelihood of unpatentability under §§ 101 and 112(a), and denying Grounds 4–6 under § 325(d).

  RulingsInstitution decision

  • PTAB / AIA Trials › Institution threshold (reasonable likelihood / more likely than not)Institution denied meritsInstitution denied

    “unless . . . the information presented in the petition . . . , if such information is not rebutted, would demonstrate that it is more likely than not that at least 1 of the claims challenged in the petition is unpatentable.” Upon considering the arguments and evidence, we determine that the information presented fails to demonstrate it is more likely than not that at least one of the challenged claims of the ’742 patent is unpatentable for ineligibility, lack of written description, or non-enablement. We also exercise our discretion to deny institution of post-grant review under 35 U.S.C. § 325(d). slip op. at 2

  • PTAB / AIA Trials › Discretionary denial › §325(d) same art / argumentsInstitution denied 325dInstitution denied

    “tramiprosate “showed a significant overall treatment effect” in “an APOE4+ sub-group,” including APOE4 homozygotes; “therapeutic interventions applied earlier in the course of AD more likely might achieve the goal of disease modification;” and that “AD would be optimally treated before significant cognitive impairment, during its pre-symptomatic or pre-clinical stages …”) (emphases removed). Accordingly, Caltagirone was previously presented to the Office and we also find that Caltagirone’s disclosures are substantially similar to, or cumulative of, other references previously considered by the Examiner.” slip op. at 49

  • Adverse judgmentAdverse judgmentOther

    “D. Statutory Disclaimer After the filing of the Petition in this proceeding, Patent Owner filed a statutory disclaimer, disclaiming claims 9 and 11–15 of the ’742 patent, effective October 7, 2022. Prelim. Resp. 12; Ex. 2001, 1. “No post-grant review will be instituted based on disclaimed claims.” 37 C.F.R. § 42.207(e). We do not analyze the validity of claims 9 and 11–15 based on Petitioner’s challenges (e.g., Grounds 2 and 3) because these claims have been statutorily disclaimed.” slip op. at 5

  • Skill levelSkill level petitioner adoptedDecided for petitioner

    “at least an M.D. or Ph.D. degree in a biomedical science or equivalent field. They would also have several years of clinical experience treating and/or conducting clinical trials of drugs for AD patients, or professional experience working in clinical trial design and execution related to drugs for AD or supervising such work. Pet. 14–15 (citing Ex. 1003 ¶ 62) (internal citation omitted). Patent Owner does not contest the characterization offered by Petitioner. Prelim. Resp. 12–13. For purposes of this Decision, we adopt Petitioner’s characterization as it is consistent with the level of skill in the art at the time of the invention as reflected by the ’742 patent and the cited prior art. See Okajima v. Bourdeau, 261 F.3d 1350, 1355 (Fed. Cir. 2001) (explaining that specific findings regarding ordinary skill level are not required “where the prior art itself reflects an appropriate level and a need for testimony is not shown” (quoting Litton Indus. Prods., Inc. v. Solid State Sys. Corp., 755 F.2d 158, 163 (Fed. Cir. 1985))).” slip op. at 9

  Claim construction§ 101 eligibility§ 112 disclosureDiscretionary denialcites Alice · Mayo · Graham
  Patents in suitUS 11,191,742
• Cambridge Associates, LLC v. Capital DynamicsAll claims unpatentable
  PTAB · Aug 31, 2015 · CBM2014-00079 · APJ Donna M Praiss · CBM · Final written decision

  Claims 1–17 are unpatentable under § 101 because they claim an abstract mathematical correlation implemented with generic computer functions.

  RulingsFinal written decision

  • Patent Eligibility (§101) › Alice/Mayo step one — 'directed to'Step1 directed to exceptionUnpatentable

    “We agree with Petitioner that Digitech is instructive guidance concerning claims to “a process that employs mathematical algorithms to manipulate existing information to generate additional information.” Digitech, 758 F.3d at 1351 (citing Parker v. Flook, 437 U.S. at 595) (concluding such claims are ineligible subject matter). Like the ’196 patent claims, the process claim in Digitech did not recite expressly mathematical formulae or equations. It claimed, in prose, generating two data sets by taking existing information, such as measured chromatic stimuli, spatial stimuli, and device response characteristic functions, and organizing the information into a new form called a device profile. Digitech, 758 F.3d at 1350–51. The method claim was determined to be an abstract idea “because it describes a process of organizing information through mathematical correlations and is not tied to a specific structure or machine.” Id. at 1350. The absence of expressly recited mathematical formulae or equations in the claim carried no significance in determining whether the claims as a whole were directed to the abstract idea. See also Alice, 134 S. Ct. at 2356–57 (noting that no special significance was given to the fact that one of the claims in Bilski reduced hedging to a mathematical formula). In sum, because we agree with Petitioner that the challenged claims involve determining a mathematical correlation, like the claims in Digitech, we conclude that the first step in the Alice/Mayo test is met for claims 1–17.” slip op. at 12

  • Patent Eligibility (§101) › Alice/Mayo step two — inventive conceptStep2 no inventive conceptUnpatentable

    “The fact that a claim relies on a method that is implemented on a computer does not, by itself, demonstrate that the claim is patent eligible. Rather, a challenged claim, properly construed, must incorporate enough meaningful limitations to ensure that what is claimed is more than just an abstract idea, and is not a mere “drafting effort designed to monopolize [an abstract idea] itself.” Mayo, 132 S. Ct. at 1297. In order for a machine to impose a meaningful limitation on the scope of a method claim, it must play “a significant part in permitting the claimed method to be performed, rather than function solely as an obvious mechanism for permitting a solution to be achieved more quickly.” SiRF Tech., Inc. v. Int’l Trade Comm’n, 601 F.3d 1319, 1333 (Fed. Cir. 2010). Claims that recite a method of doing business on a computer, and do no more than merely recite the use of the computer for its ordinary function of performing repetitive calculations, are not patent eligible. Bancorp Servs., L.L.C. v. Sun Life Assurance Co., 687 F.3d 1266, 1278–79 (Fed. Cir. 2012) (finding computer used for its most basic function, the performance of repetitive calculation, does not impose a meaningful claim limitation). We are persuaded that Petitioner has shown by a preponderance of the evidence that the extent to which a computer aids the performance of the claimed invention is no more than the ordinary function of common computer software programs, such as the Microsoft Excel spreadsheet used by Patent Owner’s expert. Reply 7 (citing Ex. 1012, 153:15–154:21). Patent Owner’s argument that the computer technology required by the ’196 patent claims “is integral to meeting the requirements of accuracy, precision and timeliness” (PO Resp. 27 (citing Ex. 2004 ¶ 96)) focuses on a specific commercial application of the patent claims “[i]n the private equity world” (id. (citing Ex. 2004 ¶¶ 86–95)). We are not persuaded by Patent Owner’s arguments because they presume particular mathematical computation methods not required by the claims, and reinforce that the nature of the invention is a patent ineligible mathematical algorithm. For example, Patent Owner contends that when presented with a problem to solve at his deposition, Petitioner’s expert, Dr. Robinson, inaccurately computed a real rate of return on an investment because he used quarterly compounding rather than daily compounding. Ex. 2004 ¶ 87. According to Mr. Reyes, Patent Owner’s expert, “daily cashflow (as opposed to monthly or quarterly) has been recognized as a requisite compounding frequency as far back as the 1960s.” Id. at ¶ 91. Such mathematical computations, even if required by the claims, are not sufficient to transform the claims into patent eligible subject matter.” slip op. at 15

  • ExcludeMotion to exclude, deniedDenied

    “For the reasons that follow, we determine that Petitioner has shown by a preponderance of the evidence that claims 1–17 of the ’196 patent are unpatentable under 35 U.S.C. § 101. Because our determination does not rely on the deposition testimony subject to Patent Owner’s Motion to Exclude, we dismiss the motion as moot.” slip op. at 2

  • Expert testimonyOther

    “We are persuaded that Petitioner has shown by a preponderance of the evidence that the extent to which a computer aids the performance of the claimed invention is no more than the ordinary function of common computer software programs, such as the Microsoft Excel spreadsheet used by Patent Owner’s expert. Reply 7 (citing Ex. 1012, 153:15–154:21). Patent Owner’s argument that the computer technology required by the ’196 patent claims “is integral to meeting the requirements of accuracy, precision and timeliness” (PO Resp. 27 (citing Ex. 2004 ¶ 96)) focuses on a specific commercial application of the patent claims “[i]n the private equity world” (id. (citing Ex. 2004 ¶¶ 86–95)). We are not persuaded by Patent Owner’s arguments because they presume particular mathematical computation methods not required by the claims, and reinforce that the nature of the invention is a patent ineligible mathematical algorithm. For example, Patent Owner contends that when presented with a problem to solve at his deposition, Petitioner’s expert, Dr. Robinson, inaccurately computed a real rate of return on an investment because he used quarterly compounding rather than daily compounding. Ex. 2004 ¶ 87. According to Mr. Reyes, Patent Owner’s expert, “daily cashflow (as opposed to monthly or quarterly) has been recognized as a requisite compounding frequency as far back as the 1960s.” Id. at ¶ 91. Such mathematical computations, even if required by the claims, are not sufficient to transform the claims into patent eligible subject matter.” slip op. at 16

  Patent outcomesUS 7,698,196 unpatentable
  § 101 eligibilitycites Alice · Mayo · Bilski
  Patents in suitUS 7,698,196

Holdings, summaries, rulings, issues, outcomes, winners and claim constructions shown for a decision were generated by a large language model reading the opinion. They are a guide to the decision, not the decision. Confirm every one against the court's own text before relying on it. Outcomes read from the patent owner’s side. Party names are extracted from the decision and are missing on about 900 short Director denials and scans, which carry the trial number instead.